Sudarshan Pharma Industries Other Announcement

Board Meeting DateAlfa AlertAn Alfa Alert is ALFA Finder's top-priority alert: filings that can move a stock, such as orders, fund raises and approvals, sent to subscribers on Telegram within seconds of reaching the exchange.

Sudarshan Pharma Industries Board Meeting Date

Sudarshan Pharma's board meets 29 October 2026 to consider Q2 results and a fund-raising proposal. Trading window remains closed until 48 hours after results.

SME to Main Board MigrationAlfa AlertAn Alfa Alert is ALFA Finder's top-priority alert: filings that can move a stock, such as orders, fund raises and approvals, sent to subscribers on Telegram within seconds of reaching the exchange.

Sudarshan Pharma Industries SME to Main Board Migration

Sudarshan Pharma's shares will list on NSE's main board from October 27, 2026, migrating from BSE SME. Trading begins under symbol SUDARSHAN, marking a platform upgrade.

Merger & Restructuring

Sudarshan Pharma Industries Merger & Restructuring

Sudarshan Pharma terminated its proposal to acquire 9.50% of Med Therapy Biotechnology Inc. The promoters' parallel 1.50% each acquisition plan also stands terminated.

Merger & Restructuring

Sudarshan Pharma Industries Merger & Restructuring Worth ₹1.4 Cr

Sudarshan Pharma Industries completed the sale of its 51% stake in subsidiary Ishwari Healthcare Private Limited for ₹1.40 Crore. The entity ceases to be a subsidiary.

Value

₹1.40 Cr

Annual General Meeting

Sudarshan Pharma Industries Annual General Meeting

Sudarshan Pharma Industries Ltd held its 18th Annual General Meeting on September 22, 2026. The meeting covered the adoption of financial statements and director re-appointment.

Acquisition

Sudarshan Pharma Industries Acquisition

Sudarshan Pharma stated its proposed 9.50% stake acquisition of Med Therapy Biotechnology Inc. remains under due diligence. Promoter acquisitions of 1.50% each are also pending.

Other AnnouncementAarti Pharmalabs Ltd AARTIPHARM

Aarti Pharmalabs Other Announcement

Aarti Pharmalabs has intimated under Regulation 46 that it revamped its website at the existing URL to improve design and accessibility. The notice has no financial or business substance.

Other AnnouncementSagarsoft (India) Ltd SAGARSOFT

Sagarsoft (India) Other Announcement

Sagarsoft (India) filed its Regulation 32 fund utilisation statement for its 2021 preferential issue. No deviation was reported and the full Rs.5.08 Crore was used.

Other AnnouncementSadhana Nitro Chem Ltd SADHNANIQ

Sadhana Nitro Chem Other Announcement

Sadhana Nitro Chem reported no deviation in use of its preferential issue proceeds for the quarter ended September 2026. The Audit Committee reviewed the statement.

Other AnnouncementShriram Asset Management Company Ltd SRAMSET

Shriram Asset Management Company Other Announcement

Shriram AMC filed ICRA's quarterly monitoring agency report on preferential issue proceeds. Utilisation is in line with the offer objects, with no deviation reported.

Other AnnouncementJhandewalas Foods Ltd JHANDEWALAS

Jhandewalas Foods Other Announcement

Jhandewalas Foods filed its quarterly shareholding pattern for the period ended September 30, 2026. The filing records holdings by category and contains no transaction or money event.

Other AnnouncementAvience Biomedicals Ltd AVIENCE

Avience Biomedicals Other Announcement

Avience Biomedicals confirmed corporate governance compliance is not applicable, as it is SME-listed on NSE Emerge. No quarterly governance report is required for September 2026.